Abstract
The authors regret that despite our best care and attention, we have discovered three errors in Table 3, as well as two corresponding errors in the text. In Table 3, Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events, one error on the AESI row for Skin reactions and two errors on the AESI row for Conjunctivitis have been corrected in Table 3 below. The corresponding text in the second sentence of the third paragraph in section 3.3. Safety should therefore read: Any-grade skin reactions (98% overall vs 44%), hypomagnesemia (39% overall vs 9%), conjunctivitis (11% overall vs 2%), arterial thromboembolic events (7% overall vs 2%), and venous thromboembolic events (6% overall vs 2%) were the most common AESIs observed more often in patients with GC + N than with GC. We have also noticed that the MedDRA preferred terms are not indented in Table 3 in the published version of the manuscript, and therefore cannot be differentiated from the AESI terms. The MedDRA preferred terms should be indented as shown in Table 3 below. The authors would like to apologise for any inconvenience caused. Table 3 Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events.[Table presented] AESIs of any grade in at least two patients in the overall phase are presented in order of any grade incidence in the GC + N group. There were no grade 5 adverse events in either treatment group. Adverse events were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The chemotherapy phase was defined as the period of time during which patients received chemotherapy in the GC + N group. AESI, adverse event of special interest; GC, gemcitabine and cisplatin; GC + N, gemcitabine and cisplatin plus necitumumab; IRR, infusion-related reaction; MedDRA, Medical Dictionary for Regulatory Activities; PPES, palmar-plantar erythrodysesthesia syndrome; TEAEs, treatment-emergent adverse events.
| Original language | English |
|---|---|
| Journal | Lung Cancer |
| DOIs |
|
| Publication status | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research
Cite this
Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer : A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62](S0169500219300212)(10.1016/j.lungcan.2019.01.005). / Watanabe, Satoshi; Yoshioka, Hiroshige; Sakai, Hiroshi; Hotta, Katsuyuki; Takenoyama, Mitsuhiro; Yamada, Kazuhiko; Sugawara, Shunichi; Takiguchi, Yuichi; Hosomi, Yukio; Tomii, Keisuke; Niho, Seiji; Yamamoto, Nobuyuki; Nishio, Makoto; Ohe, Yuichiro; Kato, Terufumi; Takahashi, Toshiaki; Kamada, Ami; Suzukawa, Kazumi; Omori, Yukie; Enatsu, Sotaro; Nakagawa, Kazuhiko; Tamura, Tomohide.
In: Lung Cancer, 01.01.2019.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer
T2 - A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62](S0169500219300212)(10.1016/j.lungcan.2019.01.005)
AU - Watanabe, Satoshi
AU - Yoshioka, Hiroshige
AU - Sakai, Hiroshi
AU - Hotta, Katsuyuki
AU - Takenoyama, Mitsuhiro
AU - Yamada, Kazuhiko
AU - Sugawara, Shunichi
AU - Takiguchi, Yuichi
AU - Hosomi, Yukio
AU - Tomii, Keisuke
AU - Niho, Seiji
AU - Yamamoto, Nobuyuki
AU - Nishio, Makoto
AU - Ohe, Yuichiro
AU - Kato, Terufumi
AU - Takahashi, Toshiaki
AU - Kamada, Ami
AU - Suzukawa, Kazumi
AU - Omori, Yukie
AU - Enatsu, Sotaro
AU - Nakagawa, Kazuhiko
AU - Tamura, Tomohide
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The authors regret that despite our best care and attention, we have discovered three errors in Table 3, as well as two corresponding errors in the text. In Table 3, Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events, one error on the AESI row for Skin reactions and two errors on the AESI row for Conjunctivitis have been corrected in Table 3 below. The corresponding text in the second sentence of the third paragraph in section 3.3. Safety should therefore read: Any-grade skin reactions (98% overall vs 44%), hypomagnesemia (39% overall vs 9%), conjunctivitis (11% overall vs 2%), arterial thromboembolic events (7% overall vs 2%), and venous thromboembolic events (6% overall vs 2%) were the most common AESIs observed more often in patients with GC + N than with GC. We have also noticed that the MedDRA preferred terms are not indented in Table 3 in the published version of the manuscript, and therefore cannot be differentiated from the AESI terms. The MedDRA preferred terms should be indented as shown in Table 3 below. The authors would like to apologise for any inconvenience caused. Table 3 Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events.[Table presented] AESIs of any grade in at least two patients in the overall phase are presented in order of any grade incidence in the GC + N group. There were no grade 5 adverse events in either treatment group. Adverse events were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The chemotherapy phase was defined as the period of time during which patients received chemotherapy in the GC + N group. AESI, adverse event of special interest; GC, gemcitabine and cisplatin; GC + N, gemcitabine and cisplatin plus necitumumab; IRR, infusion-related reaction; MedDRA, Medical Dictionary for Regulatory Activities; PPES, palmar-plantar erythrodysesthesia syndrome; TEAEs, treatment-emergent adverse events.
AB - The authors regret that despite our best care and attention, we have discovered three errors in Table 3, as well as two corresponding errors in the text. In Table 3, Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events, one error on the AESI row for Skin reactions and two errors on the AESI row for Conjunctivitis have been corrected in Table 3 below. The corresponding text in the second sentence of the third paragraph in section 3.3. Safety should therefore read: Any-grade skin reactions (98% overall vs 44%), hypomagnesemia (39% overall vs 9%), conjunctivitis (11% overall vs 2%), arterial thromboembolic events (7% overall vs 2%), and venous thromboembolic events (6% overall vs 2%) were the most common AESIs observed more often in patients with GC + N than with GC. We have also noticed that the MedDRA preferred terms are not indented in Table 3 in the published version of the manuscript, and therefore cannot be differentiated from the AESI terms. The MedDRA preferred terms should be indented as shown in Table 3 below. The authors would like to apologise for any inconvenience caused. Table 3 Treatment-emergent adverse events of special interest and hematologic treatment-emergent adverse events.[Table presented] AESIs of any grade in at least two patients in the overall phase are presented in order of any grade incidence in the GC + N group. There were no grade 5 adverse events in either treatment group. Adverse events were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The chemotherapy phase was defined as the period of time during which patients received chemotherapy in the GC + N group. AESI, adverse event of special interest; GC, gemcitabine and cisplatin; GC + N, gemcitabine and cisplatin plus necitumumab; IRR, infusion-related reaction; MedDRA, Medical Dictionary for Regulatory Activities; PPES, palmar-plantar erythrodysesthesia syndrome; TEAEs, treatment-emergent adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85064429969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064429969&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2019.04.010
DO - 10.1016/j.lungcan.2019.04.010
M3 - Comment/debate
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
ER -